

Reference: FOI.ICB-2324/130

Subject: Antidepressants

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE												
<p>Antidepressants in this instance refers to any of the following classifications of drugs: SSRIs, SNRIs, NASSAs, TCAs, SARIs, MAOIs. For ease of collation, the information could be provided in the tables provided after each question.</p>													
<p>1. The numbers of patients who have been prescribed antidepressants in the following years after a phone consultation.</p>	<p>The ICB does not hold this information</p> <table border="1" data-bbox="913 834 2157 970"> <thead> <tr> <th>2018</th> <th>2019</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023 (SO FAR)</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>	2018	2019	2020	2021	2022	2023 (SO FAR)						
2018	2019	2020	2021	2022	2023 (SO FAR)								
<p>2. The numbers of patients who have been prescribed antidepressants in the following years after one GP consultation regarding their mental health.</p>	<p>The ICB does not hold this information</p> <table border="1" data-bbox="913 1061 2157 1197"> <thead> <tr> <th>2018</th> <th>2019</th> <th>2020</th> <th>2021</th> <th>2022</th> <th>2023 (SO FAR)</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>	2018	2019	2020	2021	2022	2023 (SO FAR)						
2018	2019	2020	2021	2022	2023 (SO FAR)								

<p>Can I also confirm if there is a method by which the NHS tracks side effects experienced from use of these drugs?</p>	<p>Suspected adverse effects are monitored nationally via the national Yellow card scheme.</p> <p>Yellow Card Making medicines and medical devices safer (mhra.gov.uk) The Yellow Card scheme: guidance for healthcare professionals, patients and the public - GOV.UK (www.gov.uk)</p> <p>The MHRA produce interactive Drug Analysis Profiles (iDAPs) which contains a listing of all suspected adverse reactions that have been reported to the MHRA via the Yellow Card scheme. This includes all reports received from healthcare professionals, members of the public, and pharmaceutical companies.</p>
--	---

The information provided in this response is accurate as of 10th July 2023 and has been approved for release by Geeta Iyer, Deputy Chief Medical Officer, Primary and Community Care for NHS Bristol, North Somerset and South Gloucestershire ICB.